Skip to content

US · PHR · MEDICAL - HEALTHCARE INFORMATION SERVICES

Phreesia, Inc. (PHR) intrinsic value and stock valuation

$11.41as of 2026-11-21 · Mkt cap 710.22M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Phreesia, Inc. DCF and intrinsic value

InvestorsCraft values PHR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PHR’s statements →

Phreesia, Inc. Graham Number

Graham Number: $2.22d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Wilmington, DE 19803 phreesia.com

How the business is doing

Fiscal 2018–2026, USD

Revenue
$480.6M+26.4% 5y CAGRd
20182026
Net income
$2.31M
20182026
Free cash flow
$67.7M
20182026
Total equity
$337.2M+5.1% 5y CAGRd
20182026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2026, USD
20262025202420232022
Revenue$480.6M$419.8M$356.3M$280.9M$213.2M
Operating income-$-6.61M-$-58.1M-$-136.48M-$-176.55M-$-116.82M
Net income$2.31M-$-58.53M-$-136.88M-$-176.15M-$-118.16M
EPSd$37.6K-$-1.02M-$-2.51M-$-3.36M-$-2.37M
Operating cash flow$78.8M$32.4M-$-32.38M-$-90.12M-$-74.71M
Capital expenditure-$-11.1M-$-24.09M-$-25.1M-$-26.2M-$-30.8M
Free cash flow$67.7M$8.29M-$-57.48M-$-116.33M-$-105.52M
Total assets$663.8M$388.4M$370.3M$370.1M$494.5M
Total debt$102.5M$17.8M$12M$9.18M$15.8M
Net debt$28.6M-$-66.42M-$-75.54M-$-167.5M-$-298.01M
Total equity$337.2M$264.8M$251.5M$287.8M$417.3M
Cash and short-term investments$73.8M$84.2M$87.5M$176.7M$313.8M
Income statement
20262025202420232022
Revenue$480.6M$419.8M$356.3M$280.9M$213.2M
Cost of revenue$154.1M$134.9M$124M$109.3M$81.4M
Gross profit$326.5M$284.9M$232.3M$171.6M$131.8M
Research and development expenses$121.5M$117.4M$112.4M$91.2M$52.3M
Selling, general and administrative expenses$180.2M$197.7M$226.9M$231.7M$175.1M
Other expenses$31.5M$27.9M$29.5M$25.3M$21.3M
Operating expenses$333.1M$343M$368.8M$348.2M$248.7M
Cost and expenses$487.2M$477.9M$492.8M$457.5M$330.1M
Interest income$2.17M$2.68M$4.07M$2.48M$80K
Interest expense$6.95M$2.35M$1.85M$1.41M$1.16M
Depreciation and amortization$31.5M$27.9M$30.5M$28.8M$24.5M
Ebitda$29.5M-$-25.58M-$-102.94M-$-145.48M-$-92.3M
Operating income-$-6.61M-$-58.1M-$-136.48M-$-176.55M-$-116.82M
Total other income/expenses, net-$-2.33M$2.29M$1.14M$890K-$-1.16M
Income before tax-$-8.94M-$-55.81M-$-135.34M-$-175.66M-$-117.98M
Income tax expense-$-11.25M$2.72M$1.54M$480K$180K
Net income$2.31M-$-58.53M-$-136.88M-$-176.15M-$-118.16M
Weighted average shares outstanding$59.7M$57.6M$54.6M$52.4M$49.9M
Weighted average diluted shares outstanding$61.5M$57.6M$54.6M$52.4M$49.9M
Balance sheet
20262025202420232022
Cash and short-term investments$73.8M$84.2M$87.5M$176.7M$313.8M
Net receivables$154.6M$73.6M$64.9M$51.4M$40.3M
Inventory$0.00$0.00$770K$1.06M$1.64M
Total current assets$279.8M$203.3M$195.7M$262.4M$386.4M
Property, plant and equipment, net$23.6M$25.1M$17.2M$22.2M$37M
Goodwill and intangible assets$249.8M$156.8M$153.6M$80.3M$64M
Long-term investments$53.2M$0.00$0.00$0.00$2.44M
Total non-current assets$384M$185.1M$174.6M$107.6M$108.1M
Total assets$663.8M$388.4M$370.3M$370.1M$494.5M
Accounts payable$11.5M$5.62M$8.48M$10.8M$5.12M
Short-term debt$9.22M$9.01M$6.45M$6.11M$7.1M
Deferred revenue$49.5M$32.8M$24.1M$17.7M$16.5M
Total current liabilities$183.2M$114M$110.1M$79M$68.4M
Long-term debt$93.2M$8.8M$5.53M$5.8M$8.7M
Deferred revenue, non-current$240K$120K$100K$120K$70K
Total non-current liabilities$143.3M$9.58M$8.76M$3.2M$8.76M
Capital lease obligations$9.79M$15.9M$8.84M$8.93M$15.4M
Total liabilities$326.6M$123.6M$118.9M$82.2M$77.2M
Common stock$620K$600K$580K$540K$520K
Retained earnings-$-799.19M-$-801.5M-$-742.97M-$-606.08M-$-429.94M
Accumulated other comprehensive income (loss)-$-380K-$-50K$0.00-$0.00-$0.00
Total equity$337.2M$264.8M$251.5M$287.8M$417.3M
Total investments$53.2M$0.00$0.00$0.00$2.44M
Total debt$102.5M$17.8M$12M$9.18M$15.8M
Net debt$28.6M-$-66.42M-$-75.54M-$-167.5M-$-298.01M
Cash flow statement
20262025202420232022
Net income$2.31M-$-58.53M-$-136.88M-$-176.15M-$-118.16M
Depreciation and amortization$31.5M$27.9M$29.5M$25.3M$21.3M
Stock-based compensation$67.5M$67M$71.7M$58.8M$36.1M
Change in working capital-$-14.09M-$-6.49M-$-1.64M-$-3.86M-$-18.57M
Accounts receivable-$-10.15M-$-8.81M-$-11.21M-$-11.13M-$-10.22M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$5.26M-$-3.23M-$-1.99M$4.77M$2.88M
Net cash provided by operating activities$78.8M$32.4M-$-32.38M-$-90.12M-$-74.71M
Investments in property, plant and equipment-$-11.1M-$-8.71M-$-5.81M-$-26.2M-$-30.8M
Acquisitions, net-$-153.19M$0.00-$-14.57M$0.00-$-34.42M
Net cash used for investing activities-$-161.88M-$-24.09M-$-39.67M-$-26.2M-$-65.23M
Common stock issued$3.83M$3.93M$0.00$4.92M$245.8M
Common stock repurchased$0.00$0.00-$-12.18M-$-19.38M-$-8.99M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$72.9M-$-11.49M-$-17.11M-$-20.8M$235M
Net change in cash-$-10.39M-$-3.3M-$-89.16M-$-137.13M$95M
Cash at end of period$73.8M$84.2M$87.5M$176.7M$313.8M
Operating cash flow$78.8M$32.4M-$-32.38M-$-90.12M-$-74.71M
Capital expenditure-$-11.1M-$-24.09M-$-25.1M-$-26.2M-$-30.8M
Free cash flow$67.7M$8.29M-$-57.48M-$-116.33M-$-105.52M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Phreesia, Inc.

        Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.

        CEO
        Chaim Indig
        Employees
        1.79K
        Beta
        0.87

        Explore

        Frequently asked questions

        What is the intrinsic value of Phreesia, Inc. (PHR)?

        Phreesia, Inc. (PHR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PHR undervalued?

        PHR trades at a price of $11.41 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.